Nu-3, a Phase 2-ready candidate targeting the treatment of infected diabetic foot ulcers (iDFU), targets disruption of bacterial membranes through a unique, physical mechanism of action and has demonstrated a high barrier to resistance.

SARASOTA, Fla., July 22, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", ))), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced resistance data for Nu-3 in alignment with the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB).

The 27th Public Meeting of PACCARB convened on June 16, 2026, with discussion focused on the next 5-year iteration of the National Action Plan on Combating Antibiotic-Resistant Bacteria. The plan functions as a roadmap for the U.S. government to combat antimicrobial resistance (AMR) and guides the actions of the federal agencies that interface with AMR.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.